Literature DB >> 31798377

Prophylaxis and Management of Skin Toxicities.

Martin Salzmann1,2, Frederik Marmé1,3, Jessica C Hassel1,2.   

Abstract

Skin toxicity is a common problem not only when treating breast cancer but in all cancer types. Visible on the surface, these side effects come not just with burdening symptoms but also with stigmatization. With increasing diversity in therapeutic options, dermatologic side effects are also becoming increasingly complex and more challenging for the clinician. We reviewed the most common dermatologic side effects of current anticancer therapy, including toxicity induced by chemotherapy, targeted therapy, and immunotherapy. In particular, we focus on xerosis and pruritus, (acneiform) exanthema, hand-foot syndrome, nail toxicities, alopecia, and mucositis. We propose measures for the prevention and management of these side effects based on current literature. With high incidences in both chemotherapy and targeted therapy, prophylactic measures are crucial to reducing the incidence and severity of skin toxicity and therefore key to therapy adherence. Appropriate management of these toxicities will help avoid unnecessary treatment discontinuation.
Copyright © 2019 by S. Karger AG, Basel.

Entities:  

Keywords:  Chemotherapy; Skin toxicity; Targeted therapy

Year:  2019        PMID: 31798377      PMCID: PMC6886149          DOI: 10.1159/000497232

Source DB:  PubMed          Journal:  Breast Care (Basel)        ISSN: 1661-3791            Impact factor:   2.860


  26 in total

Review 1.  Chemotherapy-induced alopecia.

Authors:  Ralph M Trüeb
Journal:  Curr Opin Support Palliat Care       Date:  2010-12       Impact factor: 2.302

Review 2.  Nail toxicities induced by systemic anticancer treatments.

Authors:  Caroline Robert; Vincent Sibaud; Christina Mateus; Michèle Verschoore; Cécile Charles; Emilie Lanoy; Robert Baran
Journal:  Lancet Oncol       Date:  2015-04       Impact factor: 41.316

3.  Prevention of everolimus-related stomatitis in women with hormone receptor-positive, HER2-negative metastatic breast cancer using dexamethasone mouthwash (SWISH): a single-arm, phase 2 trial.

Authors:  Hope S Rugo; Lasika Seneviratne; J Thaddeus Beck; John A Glaspy; Julio A Peguero; Timothy J Pluard; Navneet Dhillon; Leon Christopher Hwang; Chaitali Nangia; Ingrid A Mayer; Timothy F Meiller; Mark S Chambers; Robert W Sweetman; J Randy Sabo; Jennifer K Litton
Journal:  Lancet Oncol       Date:  2017-03-15       Impact factor: 41.316

4.  Aprepitant for management of severe pruritus related to biological cancer treatments: a pilot study.

Authors:  Daniele Santini; Bruno Vincenzi; Francesco M Guida; Marco Imperatori; Gaia Schiavon; Olga Venditti; Anna M Frezza; Pierpaolo Berti; Giuseppe Tonini
Journal:  Lancet Oncol       Date:  2012-09-18       Impact factor: 41.316

5.  Unanticipated toxicities from anticancer therapies: survivors' perspectives.

Authors:  Mona Gandhi; Karen Oishi; Beth Zubal; Mario E Lacouture
Journal:  Support Care Cancer       Date:  2009-12-03       Impact factor: 3.603

6.  Chemotherapy-induced dermatological toxicity: frequencies and impact on quality of life in women's cancers. Results of a prospective study.

Authors:  Mark Hackbarth; Norbert Haas; Christina Fotopoulou; Werner Lichtenegger; Jalid Sehouli
Journal:  Support Care Cancer       Date:  2007-08-07       Impact factor: 3.603

7.  Nail toxicity after treatment with docetaxel: a prospective analysis in patients with advanced non-small cell lung cancer.

Authors:  Junshik Hong; Se Hoon Park; Soo Jin Choi; Seok Ho Lee; Kyu Chan Lee; Jae-Ik Lee; Sun Young Kyung; Chang Hyeok An; Sang Pyo Lee; Jeong Woong Park; Sung Hwan Jeong; Eunmi Nam; Soo-Mee Bang; Eun Kyung Cho; Dong Bok Shin; Jae Hoon Lee
Journal:  Jpn J Clin Oncol       Date:  2007-06-21       Impact factor: 3.019

8.  Cutaneous side-effects in patients on long-term treatment with epidermal growth factor receptor inhibitors.

Authors:  A Osio; C Mateus; J-C Soria; C Massard; D Malka; V Boige; B Besse; C Robert
Journal:  Br J Dermatol       Date:  2009-04-10       Impact factor: 9.302

9.  Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib.

Authors:  W J Lee; J L Lee; S E Chang; M W Lee; Y K Kang; J H Choi; K C Moon; J K Koh
Journal:  Br J Dermatol       Date:  2009-05-05       Impact factor: 9.302

Review 10.  MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy.

Authors:  Rajesh V Lalla; Joanne Bowen; Andrei Barasch; Linda Elting; Joel Epstein; Dorothy M Keefe; Deborah B McGuire; Cesar Migliorati; Ourania Nicolatou-Galitis; Douglas E Peterson; Judith E Raber-Durlacher; Stephen T Sonis; Sharon Elad
Journal:  Cancer       Date:  2014-02-25       Impact factor: 6.860

View more
  5 in total

Review 1.  The Impact of Immunological Checkpoint Inhibitors and Targeted Therapy on Chronic Pruritus in Cancer Patients.

Authors:  Alessandro Allegra; Eleonora Di Salvo; Marco Casciaro; Caterina Musolino; Giovanni Pioggia; Sebastiano Gangemi
Journal:  Biomedicines       Date:  2020-12-22

2.  Utility of cooling patches to prevent hand-foot syndrome caused by pegylated liposomal doxorubicin in breast cancer patients.

Authors:  Yan-Fu Zheng; Xin Fu; Xiao-Xu Wang; Xiao-Jing Sun; Xiao-Dan He
Journal:  World J Clin Cases       Date:  2021-11-26       Impact factor: 1.337

Review 3.  Skin Microbiome and Treatment-Related Skin Toxicities in Patients With Cancer: A Mini-Review.

Authors:  Brianna N Richardson; Jolinta Lin; Zachary S Buchwald; Jinbing Bai
Journal:  Front Oncol       Date:  2022-07-15       Impact factor: 5.738

4.  Management of Dermatologic Events Associated With the Nectin-4-directed Antibody-Drug Conjugate Enfortumab Vedotin.

Authors:  Mario E Lacouture; Anisha B Patel; Jonathan E Rosenberg; Peter H O'Donnell
Journal:  Oncologist       Date:  2022-03-11       Impact factor: 5.837

5.  An Emollient PLUS Balm Is Useful for the Management of Xerosis in Patients Treated for Cancer: A Real-World, Prospective, Observational, Multicenter Study.

Authors:  Véronique Vendrely; Ander Mayor-Ibarguren; Aline Stennevin; Ariadna Ortiz-Brugués
Journal:  Dermatol Ther (Heidelb)       Date:  2022-02-02
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.